Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| United States Department of Defense | FED |
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CoQ10 Arm 1 | Active Comparator | PharmaNord Ubiquinone 100mg/1x day |
|
| CoQ10 Arm 2 | Active Comparator | PharmaNord Ubiquinone 100mg/3x day |
|
| Placebo Arm | Placebo Comparator | Placebo (made by PharmaNord, matches active treatment) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PharmaNord Bio-Quinone Active CoQ10 Gold 100mg | Drug | Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of symptoms (out of 20 on the UCSD Symptom Score Survey) showing more favorable change (trend or effect) on active treatment vs. on placebo. | All outcomes are assessed as change from baseline. | 3.5 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percent improved on timed chair rises from Gulf War Illness Modified Lower Extremity Summary Performance Score. | All outcomes are assessed as change from baseline. | 3.5 months |
| Mean change in single-item General Self-Rated Health (GSRH). |
| Measure | Description | Time Frame |
|---|---|---|
| The investigator will assess whether there is a difference in change effect for the 100mg/day vs 300mg/day arm on symptoms. | Compare the effect of coQ10 300mg/day to placebo, and to coQ10 100mg/d on symptoms. | 3.5, 7 months |
| The investigator will assess whether there is a difference in change effect for the 100mg/day vs 300mg/day arm on timed chair rises. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Janis B Ritchie, BSN | Contact | 858-558-4950 | jbritchie@ucsd.edu |
| Name | Affiliation | Role |
|---|---|---|
| Beatrice A Golomb, MD, PhD | University of California, San Diego | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UC San Diego | Recruiting | La Jolla | California | 92093 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form | Sep 12, 2024 | Sep 12, 2024 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D018923 | Persian Gulf Syndrome |
| D028361 | Mitochondrial Diseases |
| ID | Term |
|---|---|
| D009784 | Occupational Diseases |
| D000067398 | War-Related Injuries |
| D014947 | Wounds and Injuries |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Parallel Design (primary) is followed by active treatment phase (still blind to dose).
Not provided
Not provided
Not provided
|
| PharmaNord Placebo | Drug | Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option. |
|
| PharmaNord Bio-Quinone Active CoQ10 Gold 100mg | Drug | Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option. |
|
All outcomes are assessed as change from baseline. 5 point scale, higher is good.
| 3.5 months |
| Individual GWI Symptoms | 7 validated single-item symptom self-ratings: headache; energy; fatigue with exertion, muscle pain; irritability; impatience; trouble recalling words/names. Each benefited with coQ10, p<0.05 (two-sided), in the prior coQ10 trial. | 3.5, 7 months |
| Relation of change in time to do five chair rises to change in blood level of coenzyme Q10 | Benefit to timed chair rises will relate to blood coQ10 change. This outcome assesses the relation between change in time to complete five chair rises (in seconds) to change in blood level of CoQ10 (in ug/mL). The prediction of change in time to perform five chair rises by change in coQ10 blood level (regression with robust standard errors). | 3.5, 7 months |
| Effect of CoQ10 in the majority male subset on symptoms. | Change in symptoms on coQ10 versus placebo will be assessed in men (male subset of sample). | 3.5, 7 months |
| Effect of CoQ10 in the majority male subset on timed chair rises. | Change in timed chair rises on coQ10 versus placebo will be assessed in men (male subset of sample). | 3.5, 7 months |
| Effect of CoQ10 in the majority male subset on GSRH. | Change in GSRH on coQ10 versus placebo will be assessed in men (male subset of sample). | 3.5, 7 months |
Compare the effect of coQ10 300mg/day to placebo, and to coQ10 100mg/d on timed chair rises. |
| 3.5, 7 months |
| The investigator will assess whether there is a difference in change effect for the 100mg/day vs 300mg/day arm on GSRH. | Compare the effect of coQ10 300mg/day to placebo, and to coQ10 100mg/d on GSRH. | 3.5, 7 months |
| Duration Effect on symptoms. Compare effects of 7 months vs 3.5 months of treatment, assessed at the same time point after baseline (7 months) on symptoms. | Following seven months of study participation, participants will have been on coQ10 for either 3.5 months or 7 months. These two groups will be compared to assess the impact of longer vs. shorter duration treatment (those initially randomized to placebo will crossover to active coQ10 for the final 3.5 months, while those originally randomized to coQ10 will have been on coQ10 for 7 months). | 7 months |
| Duration Effect on timed chair rises. Compare effects of 7 months vs 3.5 months of treatment, assessed at the same time point after baseline (7 months) on timed chair rises. | Following seven months of study participation, participants will have been on coQ10 for either 3.5 months or 7 months. These two groups will be compared to assess the impact of longer vs. shorter duration treatment (those initially randomized to placebo will crossover to active coQ10 for the final 3.5 months, while those originally randomized to coQ10 will have been on coQ10 for 7 months). | 7 months |
| Duration Effect on GSRH. Compare effects of 7 months vs 3.5 months of treatment, assessed at the same time point after baseline (7 months) on GSRH. | Following seven months of study participation, participants will have been on coQ10 for either 3.5 months or 7 months. These two groups will be compared to assess the impact of longer vs. shorter duration treatment (those initially randomized to placebo will crossover to active coQ10 for the final 3.5 months, while those originally randomized to coQ10 will have been on coQ10 for 7 months). | 7 months |
| Blood Pressure | Specifically, change in blood pressure on coq10 versus placebo will be assessed considering those with low blood pressure at baseline separately from those with borderline or high blood pressure at baseline. | 3.5, 7 months |
| Mitochondrial Function from blood spot card. Maximal respiration will be assessed by the "adopted transfer" technique. | 3.5, 7 months |
| Mitochondrial Function from blood spot card. Spare capacity will be assessed by the "adopted transfer" technique. | 3.5, 7 months |
| Inflammation (hsCRP) will be assessed as change from baseline and compared on active treatment vs. placebo. | 3.5, 7 months |
| Oxidative Stress | 3.5, 7 months |
| Liver Function. Alanine aminotransferase and aspartate aminotransferase will be assessed as change from baseline and compared on active treatment vs. placebo. | 3.5, 7 months |
| Dropouts for Cause. The investigator will report participants who drop out for a reason. | For instance, participants who transition from coQ10 to placebo might drop because of lost of needed benefits of coQ10 -- because the participant felt worse. Alternatively, participants who transition from placebo run-in to coQ10 might drop out due to problems like activation insomnia on active treatment. The number of dropouts will be compared on active treatment vs placebo, and the causes of dropout will be compared also. (Participants who drop because their physicians ask them to do so for some unrelated reason, not because the patient has had a problem or perceive a problem, will count as dropouts, but not as dropouts for "cause" -- cause here refers to a symptom change and/or medical event.) In addition to overall assessment, assessment of dropouts for cause will be evaluated stratified by whether the participant is transitioning from coQ10. | 3.5, 7 months |
| Relation of change in symptoms to change in blood level of coenzyme Q10 | This outcome assesses the relation between change in symptoms to change in blood level of CoQ10 (in ug/mL). | 3.5 +/- 0.5 months (priority), and ~7 months |
| Relation of change in single-item General Self-Rated Health (GSRH) to change in blood level of coenzyme Q10 | This outcome assesses the relation between change in single-item General Self-Rated Health (GSRH) to change in blood level of CoQ10 (in ug/mL). The GSRH is a 5 point scale, higher is good. | 3.5, 7 months |
| Subset effects in those citing prior coQ10 use, stratified by whether benefit had been perceived. | 3.5, 7 months |
| Analysis stratified by presence of symptoms compatible with sleep apnea | For inclusion in sleep apnea stratum during analysis, the following will be qualifying: Diagnosed sleep apnea, nocturia, awaking from sleep gasping or choking (or observed by others gasping or choking during sleep), daytime hypersomnolence, night sweats, or awaking with headache or anxiety. This is exploratory, but each outcome will be stratified by sleep apnea-compatible problems. | 3.5, 7 months |
| D009750 |
| Nutritional and Metabolic Diseases |